Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Buy at Needham & Company LLC

Needham & Company LLC upgraded shares of Clearside Biomedical (NASDAQ:CLSDGet Rating) from a hold rating to a buy rating in a report published on Thursday, The Fly reports. They currently have $5.00 price target on the stock.

A number of other equities research analysts have also weighed in on CLSD. HC Wainwright boosted their price objective on Clearside Biomedical from $5.00 to $6.00 and gave the stock a buy rating in a research report on Thursday. Stifel Nicolaus upgraded Clearside Biomedical from a hold rating to a buy rating and set a $8.00 price objective on the stock in a research report on Wednesday, November 9th. Finally, StockNews.com began coverage on Clearside Biomedical in a research report on Friday, November 4th. They set a hold rating on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $7.60.

Clearside Biomedical Stock Up 0.8 %

Shares of CLSD stock opened at $1.33 on Thursday. The firm has a market capitalization of $80.05 million, a P/E ratio of -16.63 and a beta of 1.84. Clearside Biomedical has a twelve month low of $1.00 and a twelve month high of $4.98. The stock’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.41.

Hedge Funds Weigh In On Clearside Biomedical

Institutional investors and hedge funds have recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. bought a new position in Clearside Biomedical during the first quarter valued at $181,000. GSA Capital Partners LLP bought a new position in shares of Clearside Biomedical in the first quarter worth $179,000. State Street Corp boosted its holdings in shares of Clearside Biomedical by 5.2% in the first quarter. State Street Corp now owns 193,363 shares of the company’s stock worth $443,000 after acquiring an additional 9,475 shares during the period. Bank of America Corp DE boosted its holdings in shares of Clearside Biomedical by 2,760.2% in the first quarter. Bank of America Corp DE now owns 120,500 shares of the company’s stock worth $276,000 after acquiring an additional 116,287 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of Clearside Biomedical by 314.7% in the first quarter. Jane Street Group LLC now owns 86,216 shares of the company’s stock worth $197,000 after acquiring an additional 65,424 shares during the period. 22.82% of the stock is owned by institutional investors.

About Clearside Biomedical

(Get Rating)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

Further Reading

The Fly logo

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.